Literature DB >> 19003984

Structural basis for the complete loss of GSK3beta catalytic activity due to R96 mutation investigated by molecular dynamics study.

Na Zhang1, Yongjun Jiang, Jianwei Zou, Qingsen Yu, Wenna Zhao.   

Abstract

Many Ser/Thr protein kinases, to be fully activated, are obligated to introduce a phospho-Ser/Thr in their activation loop. Presently, the similarity of activation loop between two crystal complexes, i.e. glycogen synthase kinase 3beta (GSK3beta)-AMPNP and GSK3beta-sulfate ion complex, indicates that the activation segment of GSK3beta is preformed requiring neither a phosphorylation event nor conformational changes. GSK3beta, when participated in glycogen synthesis and Wnt signaling pathways, possesses a unique feature with the preference of such substrate with a priming phosphate. Experimental mutagenesis proved that the residue arginine at amino acid 96 mutations to lysine (R96K) or alanine (R96A) selectively abolish activity on the substrates involved in glycogen synthesis signaling pathway. Based on two solved crystal structures, wild type (WT) and two mutants (R96K and R96A) GSK3beta-ATP-phospho-Serine (pSer) complexes were modeled. Molecular dynamics simulations and energy analysis were employed to investigate the effect of pSer involvement on the GSK3beta structure in WT, and the mechanisms of GSK3beta deactivation due to R96K and R96A mutations. The results indicate that the introduction of pSer to WT GSK3beta generates a slight lobe closure on GSK3beta without any remarkable changes, which may illuminate the experimental conclusion, whereas the conformations of GSK3beta and ATP undergo significant changes in two mutants. As to GSK3beta, the affected positions distribute over activation loop, alpha-helix, and glycine-rich loop. Based on coupling among the mentioned positions, the allosteric mechanisms for distorted ATP were proposed. Energy decomposition on the residues of activation loop identified the important residues Arg96 and Arg180 in anchoring the phosphate group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19003984     DOI: 10.1002/prot.22279

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  6 in total

1.  Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Authors:  Bilal Bin Hafeez; Aditya Ganju; Mohammed Sikander; Vivek K Kashyap; Zubair Bin Hafeez; Neeraj Chauhan; Shabnam Malik; Andrew E Massey; Manish K Tripathi; Fathi T Halaweish; Nadeem Zafar; Man M Singh; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

2.  Structural basis for decreased affinity of Emodin binding to Val66-mutated human CK2 alpha as determined by molecular dynamics.

Authors:  Na Zhang; Rugang Zhong
Journal:  J Mol Model       Date:  2009-10-11       Impact factor: 1.810

3.  Allosteric regulation of glycogen synthase kinase 3β: a theoretical study.

Authors:  Idit Buch; Dan Fishelovitch; Nir London; Barak Raveh; Haim J Wolfson; Ruth Nussinov
Journal:  Biochemistry       Date:  2010-12-03       Impact factor: 3.162

4.  Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.

Authors:  Yue Zhou; Na Zhang; Shan Tang; Xiaoqian Qi; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Molecules       Date:  2017-05-19       Impact factor: 4.411

5.  Chemical conversion of human epidermal stem cells into intestinal goblet cells for modeling mucus-microbe interaction and therapy.

Authors:  Andong Zhao; Hua Qin; Mengli Sun; Mao Tang; Jinyu Mei; Kui Ma; Xiaobing Fu
Journal:  Sci Adv       Date:  2021-04-14       Impact factor: 14.136

Review 6.  GSK-3 as potential target for therapeutic intervention in cancer.

Authors:  James A McCubrey; Linda S Steelman; Fred E Bertrand; Nicole M Davis; Melissa Sokolosky; Steve L Abrams; Giuseppe Montalto; Antonino B D'Assoro; Massimo Libra; Ferdinando Nicoletti; Roberta Maestro; Jorg Basecke; Dariusz Rakus; Agnieszka Gizak; Zoya N Demidenko; Lucio Cocco; Alberto M Martelli; Melchiorre Cervello
Journal:  Oncotarget       Date:  2014-05-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.